Leadership

Silk Technologies Board

brain-levyBrian Levy, OD, MSc, Executive Chairman – Dr. Levy brings more than three decades of ophthalmic industry expertise in the development of ophthalmic therapeutics. He is currently the CEO of OcuNexus Therapeutics, a development stage ophthalmic biopharmaceutical company.  Previously, he was the Chief Medical Officer (CMO) at Aerie Pharmaceuticals and a member of the executive management team that took the company public. Prior to that he served as CMO for Bausch + Lomb.  Dr. Levy has successfully led multiple NDA, PMA, and 510(k) approvals in the Ophthalmic sector in both the US and Internationally, including Europe and Asia.  Dr. Levy earned a Doctor of Optometry degree from the University of California, Berkeley.

 

Brian Lawrence, PhD, CEO, Director –  Dr. Lawrence is a co-founder of the company and co-inventor of the company’s functional technology.  He has over 12 years experience in developing silk-based materials for use in a variety of medical and commercial product applications.  Previously he was the CEO of Seryx Biomedical, and has prior experience working in the biotechnology and chemical manufacturing sector as a process engineering specialist.  Dr. Lawrence is recognized leader in the silk material development space, and has numerous publications and issued patents related to silk-based technologies.  He earned his PhD in Biomedical Engineering from Cornell University.

 

Alex Soltani, Equity Partner, Director –  Mr. Soltani Founded Skyview Capital in 2005 and is Chairman of the firm’s executive and investment committees. He is a serial entrepreneur.  Prior to founding Skyview Capital, Mr. Soltani worked at Platinum Equity and operated All Digital Communications.  Skyview Capital has completed over 30 transactions in the technology, software, and healthcare sectors.  Mr. Soltani is very involved with the operations of the portfolio companies, and works to leverage his experience to help enable rapid scaling of operations to meet both development and financial targets. Mr. Soltani holds a BA from UCLA.

 

Bill Mower, General Counsel, Director – Mr. Mower serves as General Counsel for the company and is a Partner at the Maslon law firm within the Business & Securities Group.  He represents a wide variety of clients in connection with venture startup, financing, and M&A activities.  Mr. Mower also counsels public companies in connection with their securities law compliance, general corporate matters, and represents issuers and underwriters in connection with public and private securities offerings and follow on offerings. He also assists clients with their licensing and joint venture relationships, and serves as de-facto general counsel to numerous public and private companies.

 

Emmett Cunningham, Jr, MD, PhD, MPH, Medical Advisor, Director – Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications.  Dr. Cunningham is a Managing Director at Clarus Ventures, and is an Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine.  Previously, he was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc., and worked at Pfizer Early Clinical Leader in Clinical Sciences.  Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University, and a Ph.D. in neuroscience from the University of California at San Diego.  

 

Christopher Aye, CFODirector – Mr. Aye serves as CFO for the company and is currently the CFO for Skyview Capital.  Previously, Mr. Aye served in various positions at Amgen working on multi-billion dollar M&A integrations.  Prior to Amgen, Mr. Aye served as a M&A Senior Analyst at Homestore.com, and also a Senior Associate CPA at Arthur Anderson advising start-up and emerging middle market technology companies through strategic M&A and IPO transactions.  He received a BA from the University of California, Santa Barbara, in Business Economics, and his MBA from the University of Southern California.

 

Paul M. Karpecki, OD, FAAO, Medical AdvisorDirector -Dr. Karpecki is the Director of Corneal Services and the Advanced OSD Clinic at the Kentucky Eye Institute.  He has over two decades of experience in running Dry Eye clinical trials, and has written over 1,000 publications. He has been appointed leadership roles to numerous Dry Eye related organizations, including the National Eye Institute’s Dry Eye Committee, and serves as the Chief Clinical Editor for Review of Optometry. He received his OD degree from Indiana University, and completed a fellowship in Medical Cornea and Refractive Surgery in Kansas City.

 

Medical Advisory Board

Richard L. Lindstrom, MD, Founding Partner of Minnesota Eye Consultants

Edward Holland, MD, Director of Cornea Services at Cincinnati Eye Institute

Terry Kim, MD, Professor of Ophthalmology at Duke University

Tim Comstock, OD, MS, FAAO, Ophthalmic Industry Consultant

Debra Schaumberg, ScD, OD, MPH, VP, Scientific Affairs and Real-World Evidence at Evidera of PPD, LLC